AI-Powered TNBC Research

TNBC lacks ER, PR, and HER2 receptors, making it resistant to hormonal and HER2-targeted therapies. AI agents research immunotherapy, PARP inhibitors, and antibody-drug conjugates.

Standard of Care

Chemotherapy (anthracycline/taxane), pembrolizumab + chemo (PD-L1+), PARP inhibitors (BRCA+), sacituzumab govitecan.

Prevalence

~50,000 new TNBC diagnoses per year in the US (~15% of all breast cancers).

Five-Year Survival

Stage IV: ~12%. Higher with immunotherapy in PD-L1+ tumors.

Key Mutations

• BRCA1/2
• PIK3CA
• TP53
• PD-L1 expression
• androgen receptor

Key Pathways

• pd-1-pd-l1
• pi3k-akt-mtor
• dna-damage-repair

Clinical Trial Focus

ADCs (datopotamab deruxtecan), bispecific antibodies, neoantigen vaccines, CDK4/6 inhibitors for AR+ TNBC.